Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic EGFR mutation from a phase I

	Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic EGFR mutation from a phase I
	Yuankai Shi 1; Jianying Zhou 2; Yanqiu Zhao 3; Bo Zhu 4; Liangming Zhang 5; Xingya Li 3; Jian Fang 6; Jianhua Shi 7; Zhixiang Zhuang 8; Sheng Yang 1
刊名	BMC MEDICINE
	2023
卷号	21 期号:1
ISSN号	1741-7015
英文摘要	Rezivertinib (BPI-7711) is a novel third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). This phase IIa study was part of a phase I EGFR mutated non-small cell lung cancer (NSCLC).
语种	英语
内容类型	期刊论文
源URL	[http://ir.yic.ac.cn/handle/133337/34554]
专题	中国科学院烟台海岸带研究所
作者单位	1.中国医学科学院北京协和医学院 2.浙江大学 3.郑州大学 4.Institute of Cancer, Xinqiao Hospital, Third Military Medical University 5.中国科学院烟台海岸带研究所 6.Beijing Cancer Hospital 7.Linyi Cancer Hospital 8.苏州大学 9.重庆大学 10.徐州医科大学
推荐引用方式 GB/T 7714	Yuankai Shi,Jianying Zhou,Yanqiu Zhao,et al. Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic EGFR mutation from a phase I[J]. BMC MEDICINE,2023,21(1).
APA	Yuankai Shi.,Jianying Zhou.,Yanqiu Zhao.,Bo Zhu.,Liangming Zhang.,...&Tingting Wang.(2023).Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic EGFR mutation from a phase I.BMC MEDICINE,21(1).
MLA	Yuankai Shi,et al."Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic EGFR mutation from a phase I".BMC MEDICINE 21.1(2023).